Compare Cassava Sciences Inc (FLNA) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Snowflake Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Snowflake Inc trades at $273.09 (market cap $94.23B). The key difference: Snowflake Inc is far larger — about 1773.2× Cassava Sciences Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SNOW | |
|---|---|---|
Market Cap | $53.14M | $94.23B |
Sector | Health | Technology |
52-Week High | $4.64 | $280.16 |
52-Week Low | $1.09 | $121.11 |
Enterprise Value | -$33.43M | $94.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Snowflake (SNOW) trades at $273.26, down 0.97% on the day, with strong technical momentum showing a bullish moving average signal. The company continues to deliver impressive revenue growth, reaching $3.63 billion in 2025, while maintaining consistent earnings beats in recent quarters. Analyst sentiment remains overwhelmingly positive with 80.77% buy ratings and a $297.35 consensus price target, representing 8.8% upside potential from current levels.
Despite strong growth fundamentals, Snowflake faces significant profitability challenges with a -23.79% net margin and negative ROE of -55.07%. The stock trades at premium valuations (P/S 18.4x, P/B 48.6x) while burning cash, creating execution risk. However, accelerating AI Data Cloud adoption and CEO's ambitious $184 billion market cap target by 2033 provide long-term growth catalysts if the company can achieve sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
